BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $4.29, for a total value of $34,320.00. Following the sale, the director now owns 588,754 shares in the company, valued at $2,525,754.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
BioDelivery Sciences International stock traded down $0.01 during mid-day trading on Friday, hitting $4.39. The company had a trading volume of 289,266 shares, compared to its average volume of 912,539. The company has a current ratio of 2.34, a quick ratio of 2.09 and a debt-to-equity ratio of 0.88. The stock’s 50 day moving average price is $4.09 and its two-hundred day moving average price is $4.54. BioDelivery Sciences International, Inc. has a 12 month low of $2.55 and a 12 month high of $5.37. The company has a market capitalization of $395.68 million, a PE ratio of -6.01 and a beta of 0.30.
BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.12. BioDelivery Sciences International had a negative return on equity of 0.85% and a negative net margin of 34.73%. The business had revenue of $29.68 million for the quarter, compared to the consensus estimate of $25.30 million. Equities research analysts anticipate that BioDelivery Sciences International, Inc. will post -0.14 EPS for the current year.
Several research firms recently weighed in on BDSI. Zacks Investment Research upgraded BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $5.00 price target on the stock in a research report on Tuesday, May 21st. ValuEngine downgraded BioDelivery Sciences International from a “hold” rating to a “sell” rating in a report on Thursday, August 1st. Cantor Fitzgerald set a $8.00 target price on BioDelivery Sciences International and gave the stock a “buy” rating in a report on Friday, May 10th. Finally, BidaskClub raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. BioDelivery Sciences International has a consensus rating of “Buy” and a consensus price target of $6.20.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
See Also: What does earnings per share mean?
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.